NIH R01 · 2024
Targeting PTPN11 dependent Hematologic Malignancies
Activating mutations in Protein Tyrosine Phosphatase, non-receptor type 11 (PTPN11) are seen in approximately 5-10% percent of patients with acute myeloid leukemia (AML) that independently confers a poor prognosis, and is the leukemic driver in 35% of patients with the rare chemoresistant juvenile myelomonocytic leukemia (JMML). To date, targeting PTPN11 for clinical benefit has not been well established. Our preliminary data using high-throughput functional assays have identified that PTPN11 activity is dependent on an upstream tyrosine kinase, TNK2, and that leukemic cells with activating PTPN11 mutants are sensitive to TNK2 inhibition. The long-term goal of this proposal is to identify…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.